Suppression of Transforming Growth Factor-β Effects in Rabbit Subconjunctival Fibroblasts by Activin Receptor-like Kinase 5 Inhibitor

Overview

Journal Mol Vis

Specialties Cell Biology
Molecular Biology
Ophthalmology

Date 2010 Oct 30

PMID 21031133

Citations 12

Authors

Jennifer Sapitro

Jeffrey J Dunmire

Sarah E Scott

Vijay Sutariya

Werner J Geldenhuys

Michael Hewit

Beatrice Y J T Yue

Hiroshi Nakamura

Affiliations

Soon will be listed here.

Abstract

Purpose: Transforming growth factor-β (TGF-β) activity has been implicated in subconjunctival scarring in eyes following glaucoma filtration surgery (GFS). The purpose of this study is to determine whether an inhibitor for activin receptor-like kinase (ALK) 5 (also known as TGF-β receptor type I) could suppress TGF-β activity and thereby promote filtering bleb survival after GFS in a rabbit model.

Methods: An ALK-5 inhibitor, SB-505124, was used. A docking study was performed to investigate the interaction between the inhibitor and the receptor. Immunofluorescence for connective tissue growth factor (CTGF) and α-smooth muscle actin (α-SMA) was performed in cultured rabbit subconjunctival fibroblasts. Immunoblotting for phosphorylated Smad2 (pSmad2), CTGF, and α-SMA was also performed. In an in vivo rabbit GFS model, SB-505124 was delivered in a lactose tablet during surgery. Eyes were examined by slit-lamp and intraocular pressure (IOP) was measured until the time of bleb failure or up to 28 days after surgery. Tissue sections on day 5 after surgery were histologically evaluated after staining with hematoxylin and eosin. The sections were also immunostained for CTGF and α-SMA. In addition, cell outgrowth from dissected subconjunctival tissues placed in a cell culture flask with media was investigated.

Results: The docking study indicated hydrogen bond interactions between SB-505124 and amino acids His-283 and Ser-280 of ALK-5. Suppression of pSmad2, CTGF, and α-SMA by SB-505124 was observed in cultured fibroblasts. Filtering blebs in the GFS with SB-505124 group were maintained for more than 10 days, and the period of bleb survival was significantly longer than that in controls. IOP levels after surgery seemed to be related to bleb survival. Histologically, subconjunctival cell infiltration and scarring at the surgical site in the GFS with SB-505124 and mitomycin C (MMC) groups were much subsided compared to controls. Suppression of CTGF and α-SMA by SB-505124 was also observed by immunofluorescence. Cell outgrowth from explants dissected from eyes to which SB-505124 was applied during GFS was robust while outgrowth was poor from those treated with MMC.

Conclusions: The ALK-5 inhibitor SB-505124 was efficacious both in vitro and in vivo in suppressing the TGF-β action. The inhibitor may provide a novel therapy for preventing ocular inflammation and scarring.

Citing Articles

Human transforming growth factor β type I receptor in complex with kinase inhibitor SB505124.

Rodriguez Buitrago J, Landstrom M, Wolf-Watz M Acta Crystallogr F Struct Biol Commun. 2024; 80(Pt 11):314-319.

PMID: 39441620 PMC: 11533363. DOI: 10.1107/S2053230X24010094.

Targeting Ocular Drug Delivery: An Examination of Local Anatomy and Current Approaches.

Dosmar E, Walsh J, Doyel M, Bussett K, Oladipupo A, Amer S Bioengineering (Basel). 2022; 9(1).

PMID: 35049750 PMC: 8772869. DOI: 10.3390/bioengineering9010041.

Overview of cicatricial modulators in glaucoma fistulizing surgery.

de Oliveira C, Ferreira J Int Ophthalmol. 2020; 40(10):2789-2796.

PMID: 32504309 DOI: 10.1007/s10792-020-01454-w.

Kaempferol attenuates liver fibrosis by inhibiting activin receptor-like kinase 5.

Xu T, Huang S, Huang Q, Ming Z, Wang M, Li R J Cell Mol Med. 2019; 23(9):6403-6410.

PMID: 31273920 PMC: 6714241. DOI: 10.1111/jcmm.14528.

Flavones hydroxylated at 5, 7, 3' and 4' ameliorate skin fibrosis via inhibiting activin receptor-like kinase 5 kinase activity.

Zhang Y, Wang J, Zhou S, Xie Z, Wang C, Gao Y Cell Death Dis. 2019; 10(2):124.

PMID: 30741930 PMC: 6370799. DOI: 10.1038/s41419-019-1333-7.

References

Cordeiro M . Role of transforming growth factor beta in conjunctival scarring. Clin Sci (Lond). 2003; 104(2):181-7. DOI: 10.1042/CS20020150. View

Crowston J, Akbar A, CONSTABLE P, Occleston N, Daniels J, Khaw P . Antimetabolite-induced apoptosis in Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci. 1998; 39(2):449-54. View

Massague J . How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2001; 1(3):169-78. DOI: 10.1038/35043051. View

Saika S, Yamanaka O, Baba Y, Kawashima Y, Shirai K, Miyamoto T . Accumulation of latent transforming growth factor-beta binding protein-1 and TGF beta 1 in extracellular matrix of filtering bleb and of cultured human subconjunctival fibroblasts. Graefes Arch Clin Exp Ophthalmol. 2001; 239(3):234-41. DOI: 10.1007/s004170100275. View

Cordeiro M, Mead A, Ali R, ALEXANDER R, Murray S, Chen C . Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther. 2003; 10(1):59-71. DOI: 10.1038/sj.gt.3301865. View

Cordeiro M, Reichel M, Gay J, DEsposita F, ALEXANDER R, Khaw P . Transforming growth factor-beta1, -beta2, and -beta3 in vivo: effects on normal and mitomycin C-modulated conjunctival scarring. Invest Ophthalmol Vis Sci. 1999; 40(9):1975-82. View

Sawyer J, Anderson B, Beight D, Campbell R, Jones M, Herron D . Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem. 2003; 46(19):3953-6. DOI: 10.1021/jm0205705. View

Tojo M, Hamashima Y, Hanyu A, Kajimoto T, Saitoh M, Miyazono K . The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci. 2005; 96(11):791-800. PMC: 11159601. DOI: 10.1111/j.1349-7006.2005.00103.x. View

Connor Jr T, Roberts A, Sporn M, Danielpour D, Dart L, Michels R . Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye. J Clin Invest. 1989; 83(5):1661-6. PMC: 303874. DOI: 10.1172/JCI114065. View

10.

Yamanaka R, Ogata N, Yamamoto C, Matsushita M, Matsuzaki K, Uyama M . Expression of transforming growth factor-beta receptors in normal rat retina and experimental choroidal neovascularization. Jpn J Ophthalmol. 2002; 46(5):525-32. DOI: 10.1016/s0021-5155(02)00536-1. View

11.

Swinney D . Biochemical mechanisms of drug action: what does it take for success?. Nat Rev Drug Discov. 2004; 3(9):801-8. DOI: 10.1038/nrd1500. View

12.

Jampel H, Roche N, Stark W, Roberts A . Transforming growth factor-beta in human aqueous humor. Curr Eye Res. 1990; 9(10):963-9. DOI: 10.3109/02713689009069932. View

13.

Piek E, Roberts A . Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis. Adv Cancer Res. 2001; 83:1-54. DOI: 10.1016/s0065-230x(01)83001-3. View

14.

Khaw P, Grehn F, Hollo G, Overton B, Wilson R, Vogel R . A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007; 114(10):1822-30. DOI: 10.1016/j.ophtha.2007.03.050. View

15.

Cordeiro M, Gay J, Khaw P . Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999; 40(10):2225-34. View

16.

Shah M, Foreman D, Ferguson M . Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995; 108 ( Pt 3):985-1002. DOI: 10.1242/jcs.108.3.985. View

17.

Nakamura H, Siddiqui S, Shen X, Malik A, Pulido J, Kumar N . RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Mol Vis. 2004; 10:703-11. View

18.

Grygielko E, Martin W, Tweed C, Thornton P, Harling J, Brooks D . Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther. 2005; 313(3):943-51. DOI: 10.1124/jpet.104.082099. View

19.

Olmo I, Ghaly E . Compressional characterization of two dextrose-based directly compressible excipients using an instrumented tablet press. Pharm Dev Technol. 1999; 4(2):221-31. DOI: 10.1081/pdt-100101356. View

20.

Callahan J, Burgess J, Fornwald J, Gaster L, Harling J, Harrington F . Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem. 2002; 45(5):999-1001. DOI: 10.1021/jm010493y. View